What is the mechanism of action of Lumakras?
•
4 min read
KRAS mutations are found in approximately 23% of non-small cell lung cancers (NSCLC), with the G12C mutation being the most common subtype. Lumakras, known generically as sotorasib, was the first FDA-approved targeted therapy designed specifically to address this previously 'undruggable' mutation, and its mechanism of action is both selective and irreversible.
